SPOTLIGHT: Adherex inks deal with GSK
Adherex Technologies of Research Triangle Park, North Carolina, has inked a deal in-licensing GSK's oncology product eniluracil -- with GSK retaining an option to buy it back -- and giving GSK an option to license Adherex's lead biotechnology compound, ADH-1. GSK also made a $3 million equity investment in Adherex. GSK's options in the deal could be collectively worth up to $220 million in milestones plus royalties. Release
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
